{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:31:58Z","timestamp":1759815118244},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T00:00:00Z","timestamp":1318809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Evaluation Clinical Practice"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Rationale\u2002<\/jats:bold> In Lebanon, the appropriateness of anti\u2010emetic use is questionable in large measure because of the absence of published multicentre trials.<\/jats:p><jats:p><jats:bold>Aim and objectives\u2002<\/jats:bold> To evaluate the extent of appropriateness of anti\u2010emetic use in patients on chemotherapy among several Lebanese hospitals. Appropriateness of chemotherapy\u2010induced nausea and vomiting (CINV) prophylaxis was determined as per National Comprehensive Cancer Network guidelines.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A multicentre, cross\u2010sectional study was conducted over a 3\u2010month period. Data were collected from medical charts of cancer patients. The main outcome measure was to evaluate the appropriateness of prophylactic use of anti\u2010emetics in CINV in terms of selected drug regimen, dosage and route of administration, and to investigate the role of several pre\u2010specified variables (including hospital type and size, type of insurance coverage and patient\u2010related factors) in influencing the appropriateness of anti\u2010emetic practice.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A total of 493 patients' forms were analysed. The median age was 58.8 \u00b1 13.9 years, 290 (58.8%) patients were female. Around 211 (42.8%) patients received inappropriate anti\u2010emetic regimen, and only 17 (6%) patients of those receiving appropriate regimen received the appropriate dose, and just 55 (19.5%) patients were treated for the appropriate duration. Factors that may affect the relative effectiveness of treatment were identified.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> This study reflected substantial flaws in CINV prophylaxis practice in Lebanon which should alert health care professionals of the adverse consequences resulting from non\u2010adherence to guidelines. Our study also highlighted areas for improvement and suggested recommendations in order to minimize patient risk and optimize safe and effective CINV management.<\/jats:p>","DOI":"10.1111\/j.1365-2753.2011.01770.x","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T05:03:28Z","timestamp":1318827808000},"page":"68-75","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of anti\u2010emetic use in chemotherapy\u2010induced nausea and vomiting in a third\u2010world country (Lebanon)"],"prefix":"10.1111","volume":"19","author":[{"given":"Abeer A.","family":"Zeitoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette G.","family":"Nassif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,17]]},"reference":[{"issue":"10","key":"e_1_2_8_2_2","first-page":"1","article-title":"Optimal use of antiemetics in the outpatient setting","volume":"16","author":"Grunberg S.","year":"2002","journal-title":"Oncology"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1188\/09.CJON.54-64"},{"issue":"1","key":"e_1_2_8_4_2","first-page":"10","article-title":"Chemotherapy\u2010induced nausea and vomiting","volume":"5","author":"Nevadunsky N. S.","year":"2009","journal-title":"US Oncology"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.507"},{"issue":"3","key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00520-002-0427-3","article-title":"Is delayed chemotherapy\u2010induced emesis well managed in oncological clinical practice?","volume":"11","author":"Fabi A.","year":"2003","journal-title":"Supportive Care in Cancer"},{"key":"e_1_2_8_7_2","unstructured":"Bradbury R.(2004)Optimizing antiemetic therapy for chemotherapy\u2010induced nausea and vomiting. [Document on the internet]. Available at:http:\/\/www.inetce.com\/articles\/pdf\/146-000-01-005-H01.pdf\/(last accessed February 2011)."},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00132-5"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-2-187"},{"issue":"1","key":"e_1_2_8_10_2","first-page":"41","article-title":"Cancer epidemiology in Lebanon","volume":"1","author":"Shamseddine A.","year":"2010","journal-title":"Middle East Journal of Cancer"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.12.014"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70284-9"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-9-1143"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0039"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0186-7"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0501-6"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20230"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.022"},{"key":"e_1_2_8_19_2","unstructured":"Systemic Treatment Disease Site GroupUse of 5\u2010HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Cancer Care Ontario [homepage on the internet]. Practice Guideline Report #12\u20103."},{"key":"e_1_2_8_20_2","doi-asserted-by":"crossref","unstructured":"DTB (2005)5HT3\u2010receptor antagonists as antiemetics in cancer.Drug and Therapeutics Bulletin 43(20) 57\u201362.","DOI":"10.1136\/dtb.2005.43857"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1548-5315(11)70865-8"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155207084009"},{"key":"e_1_2_8_23_2","first-page":"1","article-title":"Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic","volume":"17","author":"Iihara H.","year":"2011","journal-title":"Journal of Evaluation in Clinical Practice"}],"container-title":["Journal of Evaluation in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2753.2011.01770.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2753.2011.01770.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:15:30Z","timestamp":1697314530000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2753.2011.01770.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,17]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1365-2753.2011.01770.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2753.2011.01770.x","archive":["Portico"],"relation":{},"ISSN":["1356-1294","1365-2753"],"issn-type":[{"value":"1356-1294","type":"print"},{"value":"1365-2753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,17]]}}}